

Overview on Strokes

V. K. Koosam*

Department of Biomedicine and Methods in Medical Diagnostics,
Orebro University-70182, Sweden; vkk.sam@gmail.com

Abstract

Stroke is sudden death of brain cells due to lack of oxygen due to blood supply blockage or rupture of arteries of the brain. WHO indicates Stroke as the second leading cause for global mortality. Stroke is categorised into subtypes based on aetiology, assisting treatment evaluation.

Risk factors for stroke are age, race, heredity, hypertension, diabetes, smoking, alcohol consumption, obesity, cholesterol. Prevention methods involve lifestyle modifications, low cholesterol diet, physical activity, minimising risk factors like cigarette smoking and alcohol consumption.

Pharmacological treatments for hypertension, diabetes and interventional procedures are suggested. The prognosis depends on type extent, severity, duration of stroke and co-morbid risk factors.

Timely management of stroke, pre-hospital stroke care minimise mortality rate and enhances survival rates. Life style modifications, decrease the recurrence, thereby decrease the economic burden of stroke.

Keywords: Stroke, Pathophysiology of Stroke, Classification of Stroke, Risk Factors of Stroke, Treatment of Stroke.

1. Introduction

Stroke is focal neurological deficit, due to vascular lesion, for more than 24 hours. The blood vessel ruptures or blocked by clot, thereby the oxygen, nutrient supply is cut, causing damage to the brain tissue. The symptoms of stroke include numbness of parts or one half of the body, fainting, loss of balance, difficulty in walking, seeing, speaking or understanding and headache with no known cause. Depending on severity and part of brain affected, stroke can lead to sudden death [1].

Stroke with 5 million deaths a year (second cause of death); 15 million people suffer stroke annually, of whom one third suffer morbidity. Stroke is biggest cause of disability in United Kingdom, WHO estimates stroke events due to demographic changes in Iceland, Norway, and Switzerland to increase by 0.4 million/year (by 2025) from the present 1.1 million/year (2000). Globally stroke burden is predicted to rise from 38 million DALYs (Disability-adjusted life years) in 1990 to 61 million DALYs in thirty years. The

incidence of stroke declined in developing countries due to control of risk factors like blood pressure and reduced levels of smoking; whereas absolute number of strokes rise, due to an aging population [2–5].

2. Pathophysiology

2.1 Types of Stroke

There are different types of stroke depending on pathophysiology of the stroke.

Ischemic strokes: due to occlusion of a major cerebral artery, most commonly middle cerebral artery, by thrombus or embolism; hypotension, haemorrhage resulting from burst of blood vessel either within or on the brain's surface.

Chronic infections: Clinical research and epidemiological studies suggest multiple exposures affecting carotid arteries are associated with risk of stroke, pathogenesis atherosclerosis and progression to plaque thrombosis and rupture [8].

* Corresponding author:

V. K. Koosam (vkk.sam@gmail.com)

Deposition of atherosclerotic plaque and its subsequent rupture result in ischemia. Plaques with more lipids, localised eccentrically in the intima, are prone to rupture. The macrophages by depositing enzymes and toxic metabolites facilitate rupture. Subsequently plaque area is prone to thrombus formation by platelets activation. Further the release of vasoactive substances, increase myocardial oxygen demand; arterial spasm contributes to thrombotic occlusion leading to ischemia. As a result of thrombotic occlusion lacunar infarcts are formed contribute to stroke depending on other risk factors like diabetes, hypertension and ethnicity [9, 10].

2.2 Embolic Stroke

Emboli result from atheromatous plaque (carotid, vertebralbasilar arteries), or cardiac mural thrombi resulting from myocardial infarction or atrial fibrillation. These result in embolic stroke [1].

Air embolization occurs in procedures during neurosurgery, otolaryngology, anesthesia, central venous catheterization or from injuries and in case of divers [10].

2.3 Hypotensive Stroke

Occurs due to decrease in arterial pressure or regional haemodynamic changes, due to vessel stenosis. The areas/arteries affected to the with less or marginal blood supply are parietal-temporal-occipital triangle at the junction of the anterior, middle and posterior cerebral arteries, Watershed infarcts make up approximately 10% of all ischemic strokes, majority, around 40% of these occur in patients with carotid stenosis or occlusion [10].




Figure 1. Pathophysiology of stroke, events leading to cell death are shown in the flow chart. [14]

Rare causes of stroke: changes in blood coagulability, vasospasm, vasculitis or artery dissection [1, 6, 7].

3. Risk Factors

Risk factors can be categorised as modifiable and non modifiable risk factors.

3.1 Non modifiable Risk Factors

These risk factors cannot be modified but aids treatment in identifying those with greatest risk. The non modifiable risk factors include Age, Gender, Race, Ethnicity [1, 10–12].

Age: Is the prime, single risk factor. The stroke rate doubles for every successive age of 10 years after age 55 in both sexes; while stroke incidence are more predominant in males; the mortality rate in male per year is more than female population, as women tend to live longer than males [1, 10–12].

Heredity: Offspring analysis study revealed that both the maternal and paternal histories of stroke are associated with increased risk of stroke [1, 10–12].

Race: The mortality and incidence rates for stroke vary in different racial groups. National Health and Nutrition Examination Survey in USA revealed that the mortality rates are twice in Black Americans compared to White Americans; in age [45–55] is as much as four times higher and differences decreases as age progresses. Epidemiological studies indicate stroke death rates were similar in Hispanics and whites less than 65, but lower in those above 65. Also among the age group of 45 to 65, half of the stroke risk racial disparity is attributed to traditional risk factors like systolic blood pressure and socioeconomic factors. The incidence rates of stroke are comparatively high in Asian population (China and Japan) [1, 10–13].

3.2 Modifiable Risk Factors

Atrial fibrillation, while hypertension, Diabetes Mellitus, hyperlipidemia, smoking are major risk factors for thromboembolic stroke.

The major modifiable risk factors for stroke include Hypertension, diabetes mellitus, factors (physical activity, obesity, diet,) oral contraceptives, homocystiene, Haemostatic and Inflammatory Factors, Asymptomatic Carotid Stenosis, Transient Ischemic Attacks, Risk Factors for Recurrent Ischemia, Factors for Intracerebral and Subarachnoid Haemorrhage, Multiple risk factors. cigarette smoking, hyperlipidaemia, Cardiac Disease, alcohol, illicit

drug use, life style. The impact of these risk factors are summarised as follows [1, 11].

Hypertension: Hypertension is considered the most important single modifiable risk factor for ischemic stroke. It is a potent risk factor for Intracerebral haemorrhagic stroke (15) Relative Risk [RR] for stroke increases- from 0.5 to 4-with level of Hypertension [HTN] increasing from normal to moderate and severe HTN.

Cardiac Diseases: Cardiac diseases like Atrial fibrillation [AF], cardiac valve abnormalities (Mitral valve stenosis, mitral annular calcification) are predominant risk factors. Valvular strands are risk factors for ischemic stroke, Left atrial enlargement, cardiac structural abnormalities(patent foramen ovale (PFO) and atrial septal aneurysm (ASA) increase the riskfor embolic stroke.

Diabetes: Diabetes increases risk of ischaemic stroke and all other subtypes of stroke but has a minimal effect on Intracerebral haemorrhagic stroke. Hyperinsulinemia and insulin resistance are factors for stroke for people with normal levels of glucose [11, 15].

Smoking: Smoking cigarettes doubles the relative risk of ischemic stroke. Response in association with number of cigarettes smoked per day was more for Ischemic stroke than intercerebral haemorrhagic stroke [11, 15].

Illicit Drug Use: Illicit substances abuse like Cocaine, heroin, amphetamines, Lysergic acid diethylamide, Phencyclidine, Pentazocine, tripeleminamine, and marijuana are associated with stroke [11].

Alcohol: Increase in consumption of alcohol causes brain haemorrhage. Moderate consumption leads to reduced risk of stroke. Consumption of alcohol has a J-shaped association with ischemic stroke [11, 15].

In a Case control study involving 22 countries across the world, among middle and low income, suggests at least ten factors associated with 90%, the risk of stroke. This study also indicated that a targeted intervention of reducible risk factors like blood pressure, smoking, promotion of physical activity and a healthy diet, could substantially decrease the resulting economic burden due to stroke [15].

Classification and analysis of subtypes of stroke is essential for evaluation of prognosis of patients, their clinical treatment, and clinical studies, this subtype classification assists in evaluating recent therapeutic strategies, and evolving concepts of stroke definitions and mechanisms [16–18].

4. Classifications

4.1 TOAST Classification

The aetiology of ischemic stroke affects its prognosis, outcome and assists in management. A methodology for classification of subtypes of ischemic stroke mainly based on etiology has been developed for the Trial of Org 10172 in Acute Stroke Treatment (TOAST). Subtypes according to this classification are five subtypes of ischemic stroke that are: Large-artery atherosclerosis (LAA), cardioembolism (CE), Small-vessel/arteryocclusion (SAO), Stroke of other determined etiology (OC), and Stroke of undetermined etiology (UND) [16, 17].

4.2 ASCO Phenotypic Classification

The ASCO Classification categorises Stroke into four phenotypes using different grades for different stroke subtypes. The different Phenotypes according to ASCO include atherosclerosis (A), small vessel disease (S), cardiac source (C), and other cause (O). The different grades assigned are 1 when the potential cause of index stroke is definite, 2 for uncertain causality, 3 when presence of phenotype and uncertain causality 0 when disease is absent completely, 9 when there is no possibility of grading due to insufficient work up. The scores obtained by this system are based on levels of diagnostic evidence-: A-direct demonstration by gold standard diagnostic tests, B-indirect evidence or less sensitive specific tests, C- weak or absence of specific tests [18].

5. Current Prevention Methods

The primary stroke is the initial stroke and the secondary stroke is the subsequent strokes. Transient ischemic stroke [TIA] is a risk factors for secondary stroke.

Primary stroke prevention includes lowering blood pressure, anti-diabetic therapy, antiplatelet therapy, anti-thrombotic therapy for atrial fibrillation, life style modification (increasing physical activity, cessation of alcohol and cigarette smoking), Diet modification for lowering lipids.

Secondary stroke prevention includes lowering blood pressure, anti-diabetic therapy, treatment with an angiotensin-converting enzyme inhibitor (ACEI), angiotensin receptor blocker (ARB), antiplatelet therapy (aspirin, clopidogrel, and aspirin plus extended-release dipyridamole (ER-DP) are used in antiplatelet therapy), antithrombotic therapy in cardio embolic strokes, life style modification (increasing physical activity, cessation of alcohol and

cigarette smoking), Diet modification for lowering lipids, Endovascular or surgical treatment in extracranial or intracranial carotid or vertebral artery disease. Warfarin is used to treat patients with cardio embolic stroke with Atrial fibrillation [19–22].

6. Treatment Methods

6.1 Non-interventional Approaches

Time management is crucial in treatment of stroke. Pre-hospital and in-hospital time delays in evaluation and treatment of stroke are to be minimised. Early notification would reduce inter-hospital delays, diagnostic or imaging procedural times. A possible suggestion to reduce pre-hospital delays is a aetiology specific treatment is to be followed at the emergency site. The first inline effective treatments is administering thrombolytic agent [tissue plasminogen activator (t-PA)], this reduces the brain tissue damage and has to be given within first few hours after stroke. A structured pre-hospital stroke care approach followed prior to hospitalisation after onset of stroke ensures survival rate, and through this structured approach prioritisation of shifting patients to specialised stroke care units will minimise in-hospital delay times. A thorough synchronisation of various professionals involved (paramedics, dispatchers, nurses, emergency physicians) for effective treatment of stroke can reduce the economic burden of stroke [23–27].

6.2 Interventional Approaches

In patients with recent non-disabling strokes or TIA (Transient Ischemic Attacks) and a very high grade of stenosis carotid endarterectomy was found to be beneficial and would reduce the risk of subsequent ipsilateral cerebral ischemia and this technique requires exceptional surgical skills to avoid the risk factors involved [28–31].

7. Antihypertensive Therapy

Hypertension is the prime risk factor for stroke. Pharmacological treatment of hypertension and life style modification would prevent strokes and recurrence of TIA. The proposed drug regimen include thiazide diuretics, BBs, ACEIs, and ARBs, β -adrenergic receptor blockers, and calcium channel blockers, Nitrendipine, are beneficial in reducing cardiovascular events and stroke incidence in patients with hypertension and diabetes. Thiazide diuretics

were found to be more effective in antihypertensive therapy [32–35].

7.1 Lipid/cholesterol Lowering Therapy

Along with diet and life style modifications the recommended drug therapy is use of statins proved effective in treatment of patients with known Coronary Heart Diseases. Niacin, gemfibrozil reduces incidence of stroke in men with known Coronary Heart Diseases and low HDL/LDL cholesterol [36, 37].

Obesity: Prospective studies indicated weight reduction and maintaining BMI between 18.5 and 24.9 kg/m² and a waist circumference of <35 for women and <40 for men is recommended for overweight Ischemic patients and patients with TIA to prevent recurrence of stroke [38, 39].

7.2 Physical Activity

Physical activity decreases incidence of stroke and other coronary heart diseases. Life style modification activities like increasing physical activity will minimise pharmacological and medical interventions. Physical activity will reduce weight, blood pressure, improves glucose tolerance and enhances vasodilation [40–44].

Anticoagulants: In patients with Ischemic stroke or TIA with paroxysmal (intermittent) AF, anticoagulation with adjusted-dose warfarin and for the patients who cannot take oral anticoagulants aspirin is recommended [45–47].

7.3 Antiplatelet Therapy

In Patients with ischemic stroke or TIA with mitral valve prolapse antiplatelet therapy is reasonable. For patients who develop Intra Cerebral Haemorrhage, SubArachnoid Haemorrhage, or subdural hematoma, all anticoagulants and antiplatelet should be discontinued during the acute period for at least 1 to 2 weeks after the haemorrhage, and the anticoagulant effect should be reversed immediately with appropriate agents. For patients who require anticoagulation soon after a cerebral haemorrhage, intravenous heparin may be safer than oral anticoagulation. Oral anticoagulants may be resumed after 3 to 4 weeks, with rigorous monitoring [33, 48–53].

In patients with extra cranial vertebral artery stenosis and recurrent vertebrobasilar TIA and strokes occurring in spite of pharmacological therapy, Surgical revascularisation procedures are performed [32, 33].

8. Prognosis

Ischemic strokes have better survival rates than haemorrhagic strokes, but the recovery time is more in haemorrhagic strokes than ischemic strokes, the severity and outcome of stroke depends on extent and location of damage on the brain, duration and severity of stroke [54].

9. References

- Ballinger A, and Patchett S (2007). Essentials of Kumar and Clark clinical medicine, 4th Edn., Elsevier Saunders, 725–733.
- WHO, Stroke, Cerebrovascular accident, Available from: http://www.who.int/topics/cerebrovascular_accident/en/
- WHO, Global burden of stroke, Available from: http://www.who.int/cardiovascular_diseases/en/cvd_atlas_15_burden_stroke.pdf
- Truelsen T, Piechowski-Jóźwiak B et al. (2006). Stroke incidence and prevalence in Europe: a review of available data, *European Journal of Neurology*, vol 13(6), 581–598.
- WHO Stroke, Available from: http://www.who.int/ncd_surveillance/ncds/strokerationale/en/
- Green A R (2008). Pharmacological approaches to acute ischaemic stroke: reperfusion certainly, neuroprotection possibly, vol 153, Suppl 1, S325–S338.
- Jovičević M, Divjak I et al. (2010). Non-atherosclerotic arteriopathy as the cause of ischemic stroke among young adults. *Medicinski pregled*, vol 63(5–6), 324–332.
- Elkind M S (2010). Inflammatory mechanisms of stroke, *Stroke*, vol 41(10 Suppl), S3–S8.
- Fuster V, Stein B et al. (1990). Atherosclerotic plaque rupture and thrombosis, Evolving concepts. *Circulation*, vol 82(3 Suppl), II47–II59.
- Broussalis E, Killer M et al. (2011). Current therapies in ischemic stroke, Part A, Recent developments in acute stroke treatment and in stroke prevention, *Drug Discovery Today*.
- Sacco R L (1997). Wolf PA, American Heart Association Prevention Conference, IV. Prevention and Rehabilitation of Stroke, Risk factors, *Stroke*, (7), 507–517.
- He J, Klag M J et al. (1995). Stroke in the People's Republic of China, I. Geographic variations in incidence and risk factors, *Stroke*, (12), 2222–2227.
- Howard G, Cushman M et al. (2011). for the Reasons for geographic and racial differences in stroke (regards) investigators, Traditional risk factors as the underlying cause of racial disparities in stroke: lessons from the half-full (empty?) glass, (12), 3369–3375.
- Muthaian R, Minhas G et al. (2011). Pathophysiology of stroke and stroke induced retinal ischemia: Emerging role of stem cells. *Journal of Cellular Physiology*, doi: 10.1002/jcp.23048 [Epub ahead of print].
- O'Donnell M J, Xavier D et al. (2010). Interstroke investigators.
- Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the Interstroke study): a case-control, *Lancet*, vol 376(9735), 112–123.
- Kolominsky-Rabas P L et al. (2001) Epidemiology of ischemic stroke subtypes according to Toast criteria: incidence, recurrence, and long-term survival in ischemic stroke subtypes: a population-based study, vol 32(12), 2735–2740.
- Sumer M M, and Erturk O (2002). Ischemic stroke subtypes: risk factors, functional outcome and recurrence, *Neurological Sciences*, vol 22(6), 449–454.
- Shang W Y, and Liu J Y (2011). Stroke subtype classification: a comparative study of ASCO and modified TOAST, *Journal of the Neurological Sciences*.
- Han S W, Kim S H et al. (2007). A new subtype classification of ischemic stroke based on treatment and etiologic mechanism, vol 57(2), 96–102.
- Bardutzky J, and Schwab S (2007). Antiedema therapy in ischemic stroke, *Stroke*, vol 38(11), 3084–3094.
- Paciaroni M, and Bogousslavsky J (2010). Primary and secondary prevention of ischemic stroke, *European Neurology*, vol 63(5), 267–278.
- Bergman D (2011). Preventing recurrent cerebrovascular events in patients with stroke or transient ischemic attack: The current data, *Journal of the American Academy of Nurse Practitioners*, vol 23(12), 659–666, DOI: 10.1111/j.1745-7599.2011.00650.x
- Kessler C, Khaw AV et al. (2011). Standardized prehospital treatment of stroke, *Deutsches Ärzteblatt international*, 108(36), 585–591.
- Walter S, Kostopoulos P et al. (2010). Bringing the hospital to the patient: first treatment of stroke patients at the emergency site, *PLoS One*, vol 5(10), e13758.
- Bae H J, Kim D H et al. (2010). Prehospital notification from the emergency medical service reduces the transfer and intra-hospital processing times for acute stroke patients, *The Journal of Clinical Neurology*, vol 6(3), 138–142.
- Evenson K R, Foraker R E et al. (2009). A comprehensive review of prehospital and in-hospital delay times in acute stroke care, *International Journal of Stroke*, vol 4(3), 187–199.
- Muthaian R, Minhas G et al. (2011). Pathophysiology of stroke and stroke induced retinal ischemia: Emerging role of stem cells, *Journal of Cellular Physiology*, DOI: 10.1002/jcp.23048
- Mayberg M R, Wilson S E et al. (1991). Carotid endarterectomy and prevention of cerebral ischemia in symptomatic carotid stenosis, Veterans Affairs Cooperative Studies Program 309 Trialist Group, *JAMA*, vol 266(23), 3289–3294.

30. European Carotid Surgery Trialists' Collaborative Group (1991). MRC European Carotid Surgery Trial: interim results for symptomatic patients with severe (70–99%) or with mild (0–29%) carotid stenosis, *European Carotid Surgery Trialists' Collaborative Group, Lancet*, vol 337(8752), 1235–1243.
31. North American Symptomatic Carotid Endarterectomy Trial Collaborators (1991). Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis, *North American Symptomatic Carotid Endarterectomy Trial Collaborators, The New England Journal of Medicine*, vol 325(7), 445–453.
32. Barnett H J, Taylor D W et al. (1998). Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. *North American Symptomatic Carotid Endarterectomy Trial Collaborators, The New England Journal of Medicine*, vol 339(20), 1415–1425.
33. Storey G S, Marks M P et al. (1996). Vertebral artery stenting following percutaneous transluminal angioplasty, *Technical note, Journal of Neurosurgery*, vol 84(5), 883–887.
34. Sacco RL, Adams R et al. (2006). American Heart Association/American Stroke Association Council on Stroke, Council on Cardiovascular Radiology and Intervention, American Academy of Neurology, Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline, *Circulation*, vol 113(10), e409–449.
35. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002). The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), *JAMA*, vol 288(23), 2981–2997.
36. Tuomilehto J, Rastenyte D et al. (1999). Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. *Systolic Hypertension in Europe Trial Investigators, The New England Journal of Medicine*, vol 340(9), 677–684.
37. Amarenco P, and Tonkin A M (2004). Statins for stroke prevention: disappointment and hope, *Circulation*, vol 109(23 Suppl 1), III44–III49.
38. Rubins H B, Davenport J et al. (2001). VA-HIT Study Group. Reduction in stroke with gem fibrozil in men with coronary heart disease and low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT), *Circulation*, vol 103(23), 2828–2833.
39. Rexrode K M, Hennekens C H et al. (1997). A prospective study of body mass index, weight change, and risk of stroke in women, *JAMA*, vol 277(19), 1539–1545.
40. DiPietro L, Ostfeld A M et al. (1994). Adiposity and stroke among older adults of low socioeconomic status: the Chicago Stroke Study, *American Journal of Public Health*, vol 84(1), 14–19.
41. Lee I M, Hennekens C H et al. (1999). Exercise and risk of stroke in male physicians, *Stroke*, vol 30(1), 1–6.
42. Hu F B, Stampfer M J et al. (2000). Physical activity and risk of stroke in women, *JAMA*, vol 283(22), 2961–2967.
43. Lee C D, Folsom A R et al. (2003). Physical activity and stroke risk: a meta-analysis, vol 34(10), 2475–2481.
44. Kokkinos P F, Narayan P et al. (1995). Effects of regular exercise on blood pressure and left ventricular hypertrophy in African-American men with severe hypertension, *The New England Journal of Medicine*, vol 333(22), 1462–1467.
45. Endres M, Gertz K et al. (2003). Mechanisms of stroke protection by physical activity, *Annals of Neurology*, vol 54(5), 582–590.
46. Ezekowitz M (1998). Antithrombotics for left-ventricular impairment? *Lancet*, vol 351(9120), 1904.
47. Cleland J G, Findlay I et al. (2004). The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure, *American Heart Journal*, vol 148(1), 157–164.
48. Massie B M, Krol W F et al. (2004). The Warfarin and Antiplatelet Therapy in Heart Failure trial (WATCH): rationale, design, and baseline patient characteristics, *Journal of Cardiac Failure*, vol 10(2), 101–112.
49. Barnett H J, Jones M W et al. (1976). Cerebral ischemic events associated with prolapsing mitral valve, *Archives of Neurology*, vol 33(11), 777–782.
50. Fiorelli M, Bastianello S et al. (1999). Hemorrhagic transformation within 36 hours of a cerebral infarct: relationships with early clinical deterioration and 3-month outcome in the European Cooperative Acute Stroke Study I (ECASS I) cohort, vol 30(11), 2280–2284.
51. Ananthasubramanian K, Beattie J N et al. (2001). How safely and for how long can warfarin therapy be withheld in prosthetic heart valve patients hospitalized with a major hemorrhage? *Chest Journal*, vol 119(2), 478–484.
52. Eckman M H, Rosand J et al. (2003). Greenberg SM. Can patients be anticoagulated after intracerebral hemorrhage? A decision analysis, vol 34(7), 1710–1716.
53. Campbell N R, Hull R D et al. (1996). Aging and heparin-related bleeding, *Archives of Internal Medicine*, vol 156(8), 857–860.
54. Glazier R L, and Crowell E B (1976). Randomized prospective trial of continuous vs intermittent heparin therapy, *JAMA*, vol 236(12), 1365–1367.
55. Stroke Prognosis: What You Should Know, Available from: <http://www.caring.com/articles/stroke-prognosis>